Researchers at the University of Eastern Finland and Eberhard Karls Universität Tübingen have discovered a new molecular mechanism that can be used to inhibit the growth of hepatocellular carcinoma, which is the most common ...
May 24, 2016
0
1
Balasubramanian and Basak have recently reported quantum chemical computations that enhance our understanding of mechanisms for the causes of liver toxicity.
May 6, 2016
0
1
A new study fast-tracked for publication today in the Journal of Hepatology has shown that patients with a prior history of hepatocellular carcinoma (HCC) and who have been treated with direct-acting antivirals (DAAs) for ...
Apr 14, 2016
0
0
Data from a new study show that patients with Hepatitis C virus (HCV) taking direct-acting antiviral treatments (DAAs), who have previously fought off hepatocellular carcinoma (HCC), the most common form of liver cancer,1 ...
Apr 13, 2016
0
12
(HealthDay)—The burden of hepatitis C virus (HCV) and associated disease is projected to remain considerable even in the era of oral direct-acting antivirals (DAAs), according to a study published online March 25 in Hepatology.
Mar 30, 2016
0
11
Advances in understanding the molecular genetics of hepatocellular neoplasia have been made, and developing targeted therapeutics in combination with molecular tumor profiling may help accomplish the goal of precision treatment ...
Mar 7, 2016
0
0
International liver cancer guidelines could be preventing patients from getting life-saving treatments in developing countries, according to a new study published in the journal Heliyon. The authors of the research are calling ...
Jan 12, 2016
0
10
The conclusion drawn from a recent study that insertion of adeno-associated virus 2 (AAV2) into human DNA causes mutations leading to the development of hepatocellular carcinoma (HCC) was resoundingly rejected by leading ...
Jan 6, 2016
0
1
(HealthDay)—HIV infection has no impact on prognosis of liver transplantation (LT) for hepatocellular carcinoma (HCC), according to a study published online Oct. 30 in Hepatology.
Nov 4, 2015
0
5
(HealthDay)—For patients with hepatocellular carcinoma after radiofrequency ablation, angiotensin II receptor 1 blockers (sartans) correlate with significantly improved overall survival and time to recurrence, according ...
Oct 26, 2015
0
12
